Birdwatch Note Rating
2024-08-01 04:55:26 UTC - HELPFUL
Rated by Participant: CCD5BAB06E009970A2236B510C30E063DD29E905240AF14ECF6676DEF948FE08
Participant Details
Original Note:
Important context: This naloxone OTC approval is the culmination of a multi-year process that started in 2019, during the Trump administration. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-unprecedented-new-efforts-support-development-over#:~:text=For%20Immediate%20Release,January%2017%2C%202019 https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray#:~:text=The%20agency%20previously%20announced%20in%202019%20that%20it%20had%20designed%2C%20tested%2C%20and%20validated%20a%20model%20naloxone%20Drug%20Facts%20Label%20(DFL)%20with%20easy%2Dto%2Dunderstand%20pictograms%20on%20how%20to%20use%20the%20drug%20to%20encourage%20manufacturers%20to%20pursue%20approval%20of%20OTC%20naloxone%20products
All Note Details